Mortality Associated With Heart Failure After Myocardial Infarction

  • Yariv Gerber
    From the Department of Health Sciences Research, Division of Epidemiology (Y.G., S.A.W., C.B., A.M.C., S.M.M., R.J., V.L.R.) and Department of Cardiovascular Diseases (M.E.-S., S.M.D., V.L.R.), Mayo Clinic, Rochester, MN; Department of Internal Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY (C.B.); and Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Y.G.).
  • Susan A. Weston
    From the Department of Health Sciences Research, Division of Epidemiology (Y.G., S.A.W., C.B., A.M.C., S.M.M., R.J., V.L.R.) and Department of Cardiovascular Diseases (M.E.-S., S.M.D., V.L.R.), Mayo Clinic, Rochester, MN; Department of Internal Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY (C.B.); and Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Y.G.).
  • Maurice Enriquez-Sarano
    From the Department of Health Sciences Research, Division of Epidemiology (Y.G., S.A.W., C.B., A.M.C., S.M.M., R.J., V.L.R.) and Department of Cardiovascular Diseases (M.E.-S., S.M.D., V.L.R.), Mayo Clinic, Rochester, MN; Department of Internal Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY (C.B.); and Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Y.G.).
  • Cecilia Berardi
    From the Department of Health Sciences Research, Division of Epidemiology (Y.G., S.A.W., C.B., A.M.C., S.M.M., R.J., V.L.R.) and Department of Cardiovascular Diseases (M.E.-S., S.M.D., V.L.R.), Mayo Clinic, Rochester, MN; Department of Internal Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY (C.B.); and Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Y.G.).
  • Alanna M. Chamberlain
    From the Department of Health Sciences Research, Division of Epidemiology (Y.G., S.A.W., C.B., A.M.C., S.M.M., R.J., V.L.R.) and Department of Cardiovascular Diseases (M.E.-S., S.M.D., V.L.R.), Mayo Clinic, Rochester, MN; Department of Internal Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY (C.B.); and Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Y.G.).
  • Sheila M. Manemann
    From the Department of Health Sciences Research, Division of Epidemiology (Y.G., S.A.W., C.B., A.M.C., S.M.M., R.J., V.L.R.) and Department of Cardiovascular Diseases (M.E.-S., S.M.D., V.L.R.), Mayo Clinic, Rochester, MN; Department of Internal Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY (C.B.); and Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Y.G.).
  • Ruoxiang Jiang
    From the Department of Health Sciences Research, Division of Epidemiology (Y.G., S.A.W., C.B., A.M.C., S.M.M., R.J., V.L.R.) and Department of Cardiovascular Diseases (M.E.-S., S.M.D., V.L.R.), Mayo Clinic, Rochester, MN; Department of Internal Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY (C.B.); and Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Y.G.).
  • Shannon M. Dunlay
    From the Department of Health Sciences Research, Division of Epidemiology (Y.G., S.A.W., C.B., A.M.C., S.M.M., R.J., V.L.R.) and Department of Cardiovascular Diseases (M.E.-S., S.M.D., V.L.R.), Mayo Clinic, Rochester, MN; Department of Internal Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY (C.B.); and Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Y.G.).
  • Véronique L. Roger
    From the Department of Health Sciences Research, Division of Epidemiology (Y.G., S.A.W., C.B., A.M.C., S.M.M., R.J., V.L.R.) and Department of Cardiovascular Diseases (M.E.-S., S.M.D., V.L.R.), Mayo Clinic, Rochester, MN; Department of Internal Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY (C.B.); and Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (Y.G.).

書誌事項

タイトル別名
  • A Contemporary Community Perspective

説明

<jats:sec> <jats:title>Background—</jats:title> <jats:p>Contemporary data are lacking on the prognostic importance of heart failure (HF) after myocardial infarction (MI). We evaluated the prognostic impact of HF post MI according to preserved/reduced ejection fraction and the timing of its occurrence.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods and Results—</jats:title> <jats:p> All Olmsted County, Minnesota, residents (n=2596) with incident MI diagnosed in 1990 to 2010 and no prior HF were followed through March 2013. Cox models were used to examine (1) the hazard ratios for death associated with HF type and timing and (2) secular trends in survival by HF status. During a mean follow-up of 7.6 years, there were 1116 deaths, 634 in the 902 patients who developed HF (70%) and 482 in the 1694 patients who did not develop HF (28%). After adjustment for age and sex, HF as a time-dependent variable was strongly associated with mortality (hazard ratio =3.31, 95% confidence interval: 2.93–3.75), particularly from cardiovascular causes (hazard ratio =4.20, 95% confidence interval: 3.50–5.03). Further adjustment for MI severity and comorbidity, acute treatment, and recurrent MI moderately attenuated these associations (hazard ratio =2.49 and 2.94 for all-cause and cardiovascular mortality, respectively). Mortality did not differ by ejection fraction, but was higher for delayed- versus early-onset HF ( <jats:italic>P</jats:italic> for heterogeneity =0.002). The age- and sex-adjusted 5-year survival estimates in 2001 to 2010 versus 1990 to 2000 were 82% and 81% among HF-free and 61% and 54% among HF patients, respectively ( <jats:italic>P</jats:italic> for heterogeneity of trends =0.05). </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions—</jats:title> <jats:p>HF markedly increases the risk of death after MI. This excess risk is similar regardless of ejection fraction but greater for delayed- versus early-onset HF. Mortality after MI declined over time, primarily as a result of improved HF survival.</jats:p> </jats:sec>

収録刊行物

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ